Four trials presented at the recent American Society of Clinical Oncology (ASCO) meeting showed promise of new drug combinations or monotherapies in treating chronic lymphocytic leukemia (CLL) and ...

Insights from ASH 2025, including anticipated presentations, key takeaways, and how new research in chronic lymphocytic ...

VEN+O is a cost-effective treatment for untreated, fit CLL patients, offering superior progression-free survival and cost savings compared to most alternatives. The study used a cost-utility analysis, ...

What study showed data for zanubrutinib in previously untreated CLL? Mazyar Shadman, MD, MPH: The SEQUOIA study was a larger study with different cohorts. The randomized cohort of the study is cohort ...

AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research across multiple blood cancers including ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Dr Suchitra Sundaram looks ahead to new data on new BTK inhibitors, combination therapies, and BTK degraders to be presented ...

AbbVie is seeking a new way to fight chronic lymphocytic leukemia, or CLL, by combining its oncology drug Venclexta with another cancer-fighting drug. The North Chicago-based drugmaker has filed a ...

The global burden of chronic lymphocytic leukemia (CLL) has decreased over the past 30 years, according to a new analysis. However, the authors of the new report published in Cancer Control noted that ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to ...

For most of us, a cancer diagnosis would be the worst possible news. But a remarkable new documentary, Second Winds, captures ...